|
|
Exchange: |
OTC Bulletin Board |
Security
Type: |
Common |
Shares
Out: |
66,230,000 |
Market
Cap: |
4.11(M) |
Last
Volume: |
362,100 |
Avg
Vol: |
358,710 |
52
Week Range: |
$0.062 - $0.062 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Advaxis is a clinical-stage biotechnology company focused on the development and commercialization of proprietary Listeria monocytogenes (Lm) Technology antigen delivery products based on a platform technology that utilizes live attenuated Lm bioengineered to secrete antigen/adjuvant fusion proteins. Co.'s pipeline of product candidates include: ADXS-503, which is for the cancer indication of non-small cell lung cancer in combination with KEYTRUDA® (pembrolizumab); ADXS-504, which is for the cancer indication of early stage prostate cancer; and ADXS-PSA, which is for the cancer indication of metastatic prostate cancer in combination with KEYTRUDA® (pembrolizumab).
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
1,317,716 |
1,317,716 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
1 |
1 |
Total Buy Transactions |
0 |
0 |
1 |
1 |
Total Shares Sold |
0 |
0 |
0 |
0 |
Total Sell Value |
$0 |
$0 |
$0 |
$0 |
Total People Sold |
0 |
0 |
0 |
0 |
Total Sell Transactions |
0 |
0 |
0 |
0 |
End Date |
2024-06-27 |
2024-03-26 |
2023-09-26 |
2022-09-26 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Petit Robert |
Chief Scientific Officer |
|
2017-11-02 |
4 |
S |
$3.19 |
$40,274 |
D/D |
(12,625) |
224,640 |
|
- |
|
Lombardo Anthony A |
Interim CEO |
|
2017-11-02 |
4 |
S |
$3.19 |
$77 |
D/D |
(24) |
92,935 |
|
- |
|
Bonstein Sara |
Chief Financial Officer |
|
2017-11-02 |
4 |
S |
$3.19 |
$40,621 |
D/D |
(12,734) |
231,770 |
|
- |
|
Petit Robert |
Chief Scientific Officer |
|
2017-10-31 |
4 |
A |
$3.40 |
$1,469 |
D/D |
432 |
237,265 |
|
- |
|
Bonstein Sara |
Chief Financial Officer |
|
2017-10-31 |
4 |
A |
$3.40 |
$1,289 |
D/D |
379 |
244,504 |
|
- |
|
Gross Phillip |
10% Owner |
|
2017-10-11 |
4 |
S |
$4.30 |
$2,580,000 |
I/I |
(600,000) |
4,100,043 |
|
- |
|
Petit Robert |
Chief Scientific Officer |
|
2017-09-29 |
4 |
A |
$4.18 |
$2,136 |
D/D |
511 |
236,833 |
|
- |
|
Bonstein Sara |
Chief Financial Officer |
|
2017-09-29 |
4 |
A |
$4.18 |
$1,768 |
D/D |
423 |
244,125 |
|
- |
|
Gross Phillip |
10% Owner |
|
2017-09-26 |
4 |
S |
$4.00 |
$1,200,000 |
I/I |
(300,000) |
4,700,043 |
|
- |
|
Gross Phillip |
10% Owner |
|
2017-09-25 |
4 |
S |
$4.38 |
$1,775,315 |
I/I |
(405,323) |
5,000,043 |
|
- |
|
Gross Phillip |
10% Owner |
|
2017-09-22 |
4 |
S |
$4.68 |
$2,499,120 |
I/I |
(534,000) |
5,405,366 |
|
- |
|
Bonstein Sara |
Chief Financial Officer |
|
2017-07-31 |
4 |
A |
$6.47 |
$1,812 |
D/D |
280 |
243,429 |
|
- |
|
Petit Robert |
Chief Scientific Officer |
|
2017-07-31 |
4 |
A |
$6.47 |
$2,167 |
D/D |
335 |
236,004 |
|
- |
|
O'connor Daniel |
Chief Executive Officer |
|
2017-06-30 |
4 |
A |
$6.49 |
$4,816 |
D/D |
742 |
618,352 |
|
- |
|
Bonstein Sara |
Chief Financial Officer |
|
2017-06-30 |
4 |
A |
$6.49 |
$2,557 |
D/D |
394 |
243,149 |
|
- |
|
Petit Robert |
Chief Scientific Officer |
|
2017-06-30 |
4 |
A |
$6.49 |
$3,096 |
D/D |
477 |
235,669 |
|
- |
|
O'connor Daniel |
Chief Executive Officer |
|
2017-06-19 |
4 |
A |
$0.00 |
$0 |
D/D |
177,102 |
617,610 |
|
- |
|
Petit Robert |
Chief Scientific Officer |
|
2017-06-19 |
4 |
A |
$0.00 |
$0 |
D/D |
57,199 |
235,192 |
|
- |
|
Bonstein Sara |
Chief Financial Officer |
|
2017-06-19 |
4 |
A |
$0.00 |
$0 |
D/D |
57,199 |
242,755 |
|
- |
|
Bonstein Sara |
Chief Financial Officer |
|
2017-05-31 |
4 |
A |
$8.07 |
$1,767 |
D/D |
219 |
185,556 |
|
- |
|
Petit Robert |
Chief Scientific Officer |
|
2017-05-31 |
4 |
A |
$8.07 |
$2,139 |
D/D |
265 |
177,993 |
|
- |
|
O'connor Daniel |
Chief Executive Officer |
|
2017-05-31 |
4 |
A |
$8.07 |
$3,397 |
D/D |
421 |
440,508 |
|
- |
|
Petit Robert |
Chief Scientific Officer |
|
2017-05-01 |
4 |
A |
$0.00 |
$0 |
D/D |
57,881 |
177,728 |
|
- |
|
O'connor Daniel |
Chief Executive Officer |
|
2017-05-01 |
4 |
A |
$0.00 |
$0 |
D/D |
142,996 |
440,087 |
|
- |
|
Bonstein Sara |
Chief Financial Officer |
|
2017-05-01 |
4 |
A |
$0.00 |
$0 |
D/D |
57,881 |
185,337 |
|
- |
|
454 Records found
|
|
Page 3 of 19 |
|
|